GLP-1s and PCOS: separating real benefits from TikTok hype

What did @thejasleensingh actually say?

She said Mounjaro (tirzepatide) helps her "regulate hormones" because PCOS causes excess androgen production, leading to hair loss, acne, irregular periods, and mood issues. She framed GLP-1s as an emerging option for "metabolic and hormonal disorders" after years on birth control and a bad experience with metformin due to her missing gallbladder. She also gave a reasonably accurate (if mispronounced) breakdown of the GLP-1 drug class. The disclaimer was upfront and genuine, not buried.

To her credit, she was not claiming Mounjaro cures PCOS. She was describing personal symptom relief. That framing matters, because the science on GLP-1s and PCOS is genuinely early, and she acknowledged that directly: "the research is obviously newer." That kind of epistemic honesty is rarer than it should be in this content category.

Does the science back this up?

Partially, yes. The androgen excess explanation for PCOS symptoms is textbook-accurate. The claim that GLP-1s can help with metabolic and hormonal aspects of PCOS is supported by emerging evidence, though "regulate hormones" is doing a lot of work in that sentence.

A 2023 randomized trial by Elkind-Hirsch et al. in Fertility and Sterility found that semaglutide reduced androgen levels and improved menstrual regularity in women with PCOS and obesity. A 2022 review by Jensterle et al. in International Journal of Molecular Sciences noted that GLP-1 receptor agonists improve insulin sensitivity, which indirectly reduces ovarian androgen production. Tirzepatide specifically adds GIP agonism on top of GLP-1 activity, which may offer additional metabolic benefits, but dedicated PCOS trials for tirzepatide are still sparse as of 2024.

So the mechanism she described is real. The claim that it "regulates hormones" is a simplification, but not an irresponsible one given her framing.

What did they get wrong (or right)?

She got the androgen excess mechanism right. She got the GLP-1 vs. metformin comparison mostly right. Where she oversimplified is the phrase "regulate my hormones," which implies a more direct hormonal action than the evidence supports.

GLP-1s do not act directly on androgen receptors or ovarian hormone production. The hormonal improvements seen in PCOS patients are largely downstream of improved insulin sensitivity and weight loss, not a primary hormonal effect. That distinction matters clinically, because a patient with lean PCOS (roughly 20-30% of cases, per Lim et al., 2019, Human Reproduction Update) may not see the same hormonal benefits.

Her claim that missing a gallbladder made metformin harder to tolerate is plausible but not well-documented in the literature. Metformin's GI side effects are primarily gut-mediated, not bile-dependent. This may be her lived experience, but it is not a documented pharmacological interaction she should be citing as fact. That said, GLP-1s do carry their own GI side effect profile, and cholecystitis risk is a real consideration for patients without a gallbladder.

What should you actually know?

GLP-1 receptor agonists are not approved by the FDA specifically for PCOS. Mounjaro (tirzepatide) is approved for type 2 diabetes; Zepbound (same molecule) is approved for chronic weight management. Any use for PCOS hormone management is off-label. That does not make it wrong, but it means the evidence base is thinner and the monitoring requirements may differ from standard use cases.

If you have PCOS and are considering a GLP-1, the most relevant variables are your BMI, insulin resistance markers, and whether weight loss is a component of your treatment goal. For women with PCOS and insulin resistance or overweight/obesity, the metabolic and hormonal benefits appear real in early trials. For lean PCOS, the picture is less clear.

• Discuss androgen levels, fasting insulin, and HOMA-IR with your provider before starting.
• If you have had your gallbladder removed, flag this specifically, as GLP-1s can affect bile acid cycling.
• Birth control suppresses PCOS symptoms but does not treat the underlying condition. Coming off it, as she described, often unmasks symptoms that were previously controlled.

The bottom line on this video

This is one of the more responsible GLP-1 PCOS videos circulating right now. She does not overclaim, she cites her own experience rather than making universal statements, and she repeatedly directs viewers to their doctors. The science on GLP-1s for PCOS symptom management is real but early. Her lived experience aligns with what the preliminary data suggests for women with insulin-resistant PCOS. The "hormone regulation" framing is loose but not dangerous. The gallbladder-metformin claim is the weakest part of the video and should not be repeated as clinical rationale.